Hiding in plain sight – CRIO eSource is the biggest opportunity for sponsors. While the clinical research industry has automated many processes, there is one area that is still mostly paper-bound. This is the source of one of the greatest inefficiencies in research today. Automating this one process could drive 20% cost savings in a...
Running a Study
The FDA routinely audits clinical research sites, and some of those sites happened to use CRIO eSource on the studies in question. With our broad reach and history as the leading site-adopted eSource solution, we have now established a database of audit results that prove what we’ve known intuitively: CRIO eSource reduces audit risks for...
Running a Study
This document describes CRIO’s integrated eSource/EDC model, in which source data is collected electronically by the site using CRIO’s eSource system, then transmitted automatically to CRIO’s Reviewer module or to legacy EDC systems, which allows sponsors to review, query, code, lock and extract the data. This model unlocks significant savings for the sponsor/CRO, mainly by...
CRIO Company News
CRIO, the leader in eSource technology, is announcing the launch of an industry first, CRIO Reviewer, designed to create a fully integrated eSource/EDC system. Reviewer allows sponsors and CROs to review, query, extract, code and lock data collected in the CRIO eSource application within minutes of site completion. This solution enables research sites to capture...
CRIO Company News
Company Strengths Executive Management Team with Senior Industry Expert BOSTON, MA – April 19, 2022 – Clinical Research IO (CRIO), a Boston-based technology firm streamlining clinical trials for sponsors, sites, and patients, announced that Jonathan Andrus will join as President and Chief Operating Officer. Working collaboratively with the CRIO senior team, Andrus will focus on...
CRIO Company News
While much of the research and development conducted by the global pharmaceutical industry relies on cutting-edge technology, one aspect of the process of developing and testing new drugs is decidedly low tech: clinical research. That’s what Raymond Nomizu, a Harvard-trained lawyer and former management consultant discovered when he decided to launch a company focusing on...
